🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

4 recruiting trials

for IBI363 + Chemotherapy

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer NCT07408635Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: IBI363 + Chemotherapy IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687Phase 21 site📍 Shenyang Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pemetrexed, Cisplatin, IBI363, Carboplatin, Keytruda Study of IBI363 in Patients with Advanced First-line Gastric Cancer NCT06610799Phase 11 site📍 Hangzhou Xiangdong Cheng · Tests: IBI363 Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer NCT07325630Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: IBI363 + chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy